Prof. Dr. med. Uwe Reinhold

Facharzt für Dermatologie

Prof. Dr. med. Uwe Reinhold ist Facharzt für Dermatologie und blickt auf eine langjährige berufliche Erfahrung in der Behandlung von Haut- und Haarerkrankungen zurück. Insbesondere ist er ein angesehener Experte im Bereich des Hautkrebses. Hierfür wird unser Hautarzt Prof. Reinhold jährlich von FOCUS-Gesundheit als Top-Mediziner ausgezeichnet.

Er besitzt Qualifikationen in den Bereichen Lasermedizin, medikamentöse Tumortherapie, Allergologie und Venerologie.

Hautarzt Prof. Dr. Uwe Reinhold
Prof. Dr. Reinhold ist Top-Mediziner 2022 im Bereich Hauttumore
Hautärzte (Dermatologen)
in Bonn auf jameda

Tätigkeitsschwerpunkte

Berufliche Expertise

seit 2013
Leitender Arzt und Facharzt für Dermatologie, MVZ Dermatologisches Zentrum Bonn

bis 2012
Medizinisches Zentrum Bonn Friedensplatz – Abteilung Dermatologie

seit 2012
Vorsitzender von Onkoderm e.V. (Bundesweites Netzwerk niedergelassener Dermato-Onkologen)

seit 2006
Mitgründer und Leiter des Fachbereiches Dermatologie, Allergologie und Dermatologische Onkologie, Medizinischen Zentrums Bonn Friedensplatz

2002 bis 2006
Gründung der Dermato-onkologischen Praxisklink Bonn in Bonn-Beuel

2001
Preisträger des Deutschen Hautkrebspreises 2001 in Wien

1998
Ernennung zum Professor für Dermatologie und Venerologie

1997 bis 2002
Leitender Oberarzt und stellvertretender Klinikdirektor der Universitäts-Hautklinik und Poliklinik der Universitätskliniken des Saarlandes, Homburg/Saar

1994
Habilitation im Fach Dermatologie und Venerologie an der Medizinischen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn

1993 bis 1997
Oberarzt an der Universitäts-Hautklinik Bonn-Venusberg

1988 bis 1992
Facharztausbildung an der Universitäts-Hautklinik Bonn-Venusberg

Promotionsthema: Immunologische Veränderungen bei atopischer Dermatitis

  • Laboruntersuchungen Teil 1 und 2
  • Medikamentöse Tumortherapie
  • Allergologie
  • Arzt im Rettungsdienst
  • Tropendermatologie und Reisemedizin

Bücher

Reinhold U, Dirschka T, Koch P.
Notfälle in der Dermatologie. Ein aktueller Leitfaden für Klinik und Praxis.
2. Auflage 2012. Georg Thieme Verlag, Stuttgart, New York.

Reinhold U, Breitbart E (Eds.)
Hautkrebsprävention – Früherkennung und Vorbeugung.
Schlütersche Verlagsgesellschaft Hannover 2007.

Tilgen W, Dill-Müller D, Koch P, Reinhold U.
Empfehlungen zur Patienteninformation – Dermatologie.
2002. Steinkopf Verlag Darmstadt.

Reinhold U, Tilgen W (Eds.)
Chemosensitivity Testing in Oncology. Recent Results in Cancer Research
Vol. 161, Springer Verlag Berlin, Heidelberg, New York 2002.

Reinhold U, Tilgen W (Eds.)
Minimal Residual Disease in Melanoma. Recent Results in Cancer Research
Vol. 158, Springer Verlag Berlin, Heidelberg, New York, 2000.

Weitere Veröffentlichungen

Reinhold U, Bai-Habelski J, Abeck D, Denfeld R, Dominicus R, Fischer T, Radny P.
Kaliumhydroxid-5 %-Lösung bei aktinischer Keratose : Ein neuer Therapieansatz zur läsionsgerichteten Behandlung [Potassium hydroxide 5 % solution in actinic keratosis : A novel therapeutic approach in the lesion-directed treatment]. Hautarzt. 2021 Nov;72(11):975-983. German. doi: 10.1007/s00105-021-04888-0. Epub 2021 Aug 13. PMID: 34387709; PMCID: PMC8536816.

Ulrich M, Reinhold U, Dominicus R, Aschoff R, Szeimies RM, Dirschka T.
Red light photodynamic therapy with BF-200 ALA showed superior efficacy in the treatment of actinic keratosis on the extremities, trunk, and neck in a vehicle-controlled phase III study. J Am Acad Dermatol. 2021 Dec;85(6):1510-1519. doi: 10.1016/j.jaad.2021.03.031. Epub 2021 Mar 17. PMID: 33744350.

Gambichler T, Tsagoudis K, Kiecker F, Reinhold U, Stockfleth E, Hamscho R, Egberts F, Hauschild A, Amaral T, Garbe C.
Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients. Eur J Cancer. 2021 Jan;143:11-18. doi: 10.1016/j.ejca.2020.10.016. Epub 2020 Dec 2. PMID: 33278769.

Termeer C, Reinhold U, Dirschka T, von Kiedrowski R, Kurzen H.
Long-term use of fumaric acid esters for the treatment of psoriasis in daily practice. J Dermatolog Treat. 2021 Sep;32(6):610-616. doi: 10.1080/09546634.2019.1688234. Epub 2019 Nov 12. PMID: 31682772.

Stockfleth E, Hofbauer GFL, Reinhold U, Popp G, Hengge UR, Szeimies RM, Brüning H, Anliker M, Hunger T, Dummer R, Ulrich C, Kenzelmann R, Surber C, French LE.
Topical resiquimod dosing regimens in patients with multiple actinic keratoses: a multicentre, partly placebo-controlled, double-blind clinical trial. Br J Dermatol. 2019 Feb;180(2):297-305. doi: 10.1111/bjd.17124. Epub 2018 Oct 22. PMID: 30171698.

Reinhold U, Petering H, Dirschka T, Rozsondai A, Gille J, Kurzen H, Ostendorf R, Ebeling A, Stocker M, Radny P.
Photodynamic therapy with a 5-ALA patch does not increase the risk of conversion of actinic keratoses into squamous cell carcinoma: Results of a multicentre non-interventional study. Exp Dermatol. 2018 Dec;27(12):1399-1402. doi: 10.1111/exd.13804. PMID: 30326156.

Morton CA, Dominicus R, Radny P, Dirschka T, Hauschild A, Reinhold U, Aschoff R, Ulrich M, Keohane S, Ekanayake-Bohlig S, Ibbotson S, Ostendorf R, Berking C, Gröne D, Schulze HJ, Ockenfels HM, Jasnoch V, Kurzen H, Sebastian M, Stege H, Staubach P, Gupta G, Hübinger F, Ziabreva I, Schmitz B, Gertzmann A, Lübbert H, Szeimies RM.
A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy. Br J Dermatol. 2018 Aug;179(2):309-319. doi: 10.1111/bjd.16441. Epub 2018 May 16. PMID: 29432644.

Holmes J, von Braunmühl T, Berking C, Sattler E, Ulrich M, Reinhold U, Kurzen H, Dirschka T, Kellner C, Schuh S, Welzel J. Optical coherence tomography of basal cell carcinoma: influence of location, subtype, observer variability and image quality on diagnostic performance. Br J Dermatol. 2018 May;178(5):1102-1110. doi: 10.1111/bjd.16154. Epub 2018 Mar 25. PMID: 29193003.

Reinhold U. A review of BF-200 ALA for the photodynamic treatment of mild-to-moderate actinic keratosis. Future Oncol. 2017 Nov;13(27):2413-2428. doi: 10.2217/fon-2017-0247. Epub 2017 Aug 14. PMID: 28805092.

Reinhold U, Hadshiew I, Melzer A, Prechtl A. Low-dose 5-fluorouracil in combination with salicylic acid for the treatment of actinic keratoses on the hands and/or forearms – results of a non-interventional study. J Eur Acad Dermatol Venereol. 2017 Mar;31(3):455-462. doi: 10.1111/jdv.13935. Epub 2016 Sep 23. PMID: 27549913.

Ulrich M, Reinhold U, Skov T, Elvang Søndergaard R, Guitera P. Histological examination confirms clinical clearance of actinic keratoses following treatment with ingenol mebutate 0·05% gel. Br J Dermatol. 2017 Jan;176(1):71-80. doi: 10.1111/bjd.14968. Epub 2016 Dec 7. PMID: 27518593.

Reinhold U, Dirschka T, Ostendorf R, Aschoff R, Berking C, Philipp-Dormston WG, Hahn S, Lau K, Jäger A, Schmitz B, Lübbert H, Szeimies RM. A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz(®) ) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED(®) lamp. Br J Dermatol. 2016 Oct;175(4):696-705. doi: 10.1111/bjd.14498. Epub 2016 Jun 25. PMID: 26921093.

U. Reinhold, T. Dirschka, R. Ostendorf, R. Aschoff, C. Berking, W.G. Philipp-Dormston, S. Hahn, K. Lau, A. Jäger, B. Schmitz, H. Lübbert and R.-M. Szeimies
A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz“) vs. placebo in the field-directed treatment of mild-to- moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED“ lamp
British Journal of Dermatology (2016)

Mohr P, Birgersson U, Berking C, Henderson C, Trefzer U, Kemeny L, Sunderkötter C, Dirscka T, Motley R, Frohm-Nilson M, Reinhold U, Loquai C, Braun R, Nyberg F, Paoli J
Electrical impedance spectorscopy as a potential adjunct diagnostic tool for cutaneous melanoma.
Skin Research and Technology 2013;19:75-83.

Schmitz L, Reinhold U, Bierhoff E, Dirschka,T
Optical coherenzce tomography: its role in daily dermatological practice.
J Dtsch Dermatol Ges 2013;11:499-507.

Dirschka T, Radny P, Dominicus R, Mensing H, Brüning H, Jenne L, Karl L, Sebastian M, Oster-Schmidt C, Klövekorn W, Reinhold U, Tanner M, Gröne D, Deichmann M, Simon M, Hübinger F, Hofbauer G, Krähn-Senftleben G, Borrosch F, Reich K, Berking C, Wolf P, Lehmann P, Moers-Carpi M, Hönigsmann H, Wernicke-Panten K, Helwig C, Foguet M, Schmitz B, Lübbert H, Szeimies RM
Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multi-centre, randomized, oberserver-blind phase III study in comparison with a registered methyl-aminolaevulinate cream and placebo. ,
Br J Dermatol. 2012 Jan;166(1):137-46

Reinhold U, Dirschka T, Hartgens K, Kirchesch H, Ostendorf R, Petering H, Prieur H, Krähn-Senftleben G, Malaisse WJ
Vitamin D supply: from sun or pill ? Attitudes and recommendation on vitamin D and impact on sun protection practices among German general practitioners evaluated by the network of dermato-oncologists
Onkoderm e.V. Oncol Lett. 2012 Dec;4(6):1392-1396. Epub 2012 Sep 26.

The AK-CT002 and AK-CT003 Study Groups, Dirschka T, Radny P, Dominicus R, Mensing H, Brüning H, Jenne L, Karl L, Sebastian M, Oster-Schmidt C, Klövekorn W, Reinhold U, Tanner M, Gröne D, Deichmann M, Simon M, Hübinger F, Hofbauer G, Krähn-Senftleben G, Borrosch F, Reich K, Berking C, Wolf P, Lehmann P, Moers-Carpi M, Hönigsmann H, Wernicke-Panten K, Hahn S, Pabst G, Voss D, Foguet M, Schmitz B, Lübbert H, Szeimies RM
Long-term (6 and 12 months) follow-up of two prospective, randomized, cotrolled phase III trials of photodynamic therapy with BF-200 ALA and MAL for the treatment of actinic keratosis.
Br J Dermatol. 2012 Dec 18. doi: 10.1111/bjd.12158. [Epub ahead of print]

Reinhold U
Electrochemotherapy for primary skin cancer and skiReinhold U,n metastases related to other malignances Anticancer Drugs.
2011 Sep;22(8):711-8.

Reinhold U
Elektrochemotherapy.
Hautarzt. 2011 Jul;62(7):549-58

Szeimies RM, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, Mensing H, Reinhold U, Reich K, Moor AC, Stocker M, Ortland C, Brunnert M, Hauschild A
Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data.
Br J Dermatol. 2010 Feb 1;162(2):410-4. doi: 10.1111/j.1365-2133.2009.09377.x. Epub 2009 Jun 30

Szeimies RM, Radny P, Sebastian M, Borrosch F, Dirschka T, Krähn-Senftleben G, Reich K, Pabst G, Voss D, Foguet M, Gahlmann R, Lübbert H, Reinhold U, Reich K, Moor AC, Stocker M, Ortland C, Brunnert M, Hauschild A
Photodynamic therapy mit BF-200 ALA for the treatment of actinic keratosis:results of a prospective, randomized, doule-blind, placebo-controlled phase III study.
Br J Dermatol. 2010 Aug;163(2):386-94. doi: 10.1111/j.1365-2133.2010.09873.x. Epub 2010 May 28

Hauschild A, E. Stockfleth, G. Popp, F. Borrosch, H. Brüning, R. Dominicus, H. Mensing, Reinhold U, K. Reich, A.C.E. Moor, M. Stocker, C. Ortland, M. Brunnert and R.-M. Szeimies.
Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies (BJD British Journal of Dermatology)
2009 May; 160 (5):1066-74 Epub 2009 Geb 16

Knight LA, Kurbacher CM, Glaysher S, Fernando A, Reichelt R, Dexel S, Reinhold U
Cree IA Activity of mevolonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay.
BMC Cancer. 2009 Jan 28, 9:38.

Szeimies RM, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, Mensing H, Reinhold U, Reich K, Moor AC, Stocker M, Ortland C, Brunnert M, Hauschild
A Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data.
Br J Dermatol. 2009 Jun 30.

Hauschild A, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, Mensing H, Reinhold U, Reich K, Moor AC, Stocker M, Ortland C, Brunnert M, Szeimies RM
Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies.
Br J Dermatol. 2009 May;160(5):1066-74. Epub 2009 Feb 16.

Claus Garbe, Axel Hauschild, Matthias Volkenandt, Dirk Schadendorf, Wilhelm Stolz, Reinhold U, Rolf-Dieter Kortmann, Christoph Kettelhack, Bernhard Frerich, Ulrich Keilholz, Reinhard Dummer, Günther Sebastian, Wolfgang Tilgen, Gerold Schuler, Andreas Mackensen and Roland Kaufmann
Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting.
Melanoma Research. 18(2):152-160, April 2008.

Hauschild A, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, Mensing H, Reinhold U, Reich K, Moor ACE, Stocker M, Ortland C, Brunnert M, Szeimies R. Br.
Optimisation of photodynamic therapy with a novel self-adhesive 5-ALA patch: Results of two randomised controlled phase III studies.
J. Dermatol. (2008)

Reinhold U, Barbara Schmitz, Christian Kurbacher, Wolfgang Nagel, Matthias Schmidt and Willy J. Malaisse
Circulating 25-hydroxyvitamin D concentration in German cancer patients. (Medical Center Bonn Friedensplatz, 16 Friedensplatz, D-53111 Bonn, Germany; 2Laboratory of Experimental) Hormonology, Brussels Free University, 808 Route de Lennik, B-1070 Brussels, Belgium
Oncology Reports 20: 1539-1543, 2008.

Reinhold U, Breitbart E (Eds)
Hautkrebsprävention – Früherkennung und Vorbeugung.
Schlütersche Verlagsgesellschaft 2007.

Reinhold U, Breitbart E (Eds)
Ambulante dermatologische Chemotherapie.
Hautarzt 2007;58:77-93.

Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R
Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma.
Melanoma Res. 2007 Dec;17(6):393-9.

Buzug TM, Schumann S, Pfaffmann L, Reinhold U, Ruhlmann J.
Functional infrared imaging for skin-cancer screening.
Conf Proc IEEE Eng Med Biol Soc. 2006;1:2766-9.

Ladewig G, Reinhold U, Thirkill CE, Kerber A, Tilgen W, Pföhler C
Nachsorge und Behandlung des Melanoms in der dermatologischen Praxis
Garbe C. Managment des Melanoms. 2006. Springer-Verlag, Heidelberg.

Ugurel S., Schadendorf D., Pföhler C., Neuber K., Thoelke A., Ulrich J., Hauschild A., Spieth K., Kaatz M., Rittgen W., Delorme S., Tilgen W., Reinhold U
In vitro Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in metastatic Melanoma: a Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group.
Clin Cancer Res 2006;12(18):5454-5463

Dirschka Th, Reinhold U, Rosenbach Th, Schubert E, Sebastian M, Streit V
Efalizumab-Therapie der mittelschweren bis schweren Plaque-Psoriasis in der Hautarztpraxis.
JDDG 2006, Supplement 1:S3-S12.

Reinhold U
Pigmentzelltumor. Diagnostische und therapeutische Überlegungen.
Rheinisches Ärzteblatt 1/2005

Tilgen W, Dill-Müller D, Koch P Reinhold U
Empfehlungen zur Patienteninformation Dermatologie.
Steinkopff Verlag 2005.

Bornholdt D, Konig A, Happle R, Leveleki L, Bittar M, Danarti R, Vahlquist A, Tilgen W, Reinhold U, Poiares Baptista A, Grosshans E, Vabres P, Niiyama S, Sasaoka K, Tanaka T, Meiss AL, Treadwell PA, Lambert D, Camacho F, Grzeschik KH
Mutational spectrum of NSDHL in CHILD syndrome.
J. Med. Genet. (2005) 42:e17

Cree IA, Neale MH, Reinhold U, Kurbacher CM
Treosulfan and gemcitabine.
J. Cancer Res. Clin. Oncol. 2005 Feb 8

Reinhold U
Interdisziplinäre Leitlinien zur Diagnostik und Behandlung von Hauttumoren.
Georg Thieme Verlag Stuttgart New York, 2005.

Kurbacher Ch., Kurbacher J.A., Cramer E.M., Rhiem K, Mallmann P.K., Reichelt R., Reinhold U, Stier U., Cree, I.A.
Continuos low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma.
Oncology 2005;19 (Supplement):23-26.

Ladewig G, Reinhold U, Thirkill CE, Kerber A, Tilgen W, Pföhler C
Incidence of antiretinal antibodies in melanoma: screening of 77 serum samples from 51 patients with American Joint Committee on Cancer stage I-IV.
Br. J. Dermatol. (2005) 152:931-8.

Ugurel S, Uhlig D, Pföhler C, Tilgen W, Schadendorf D, Reinhold U, Schöpf E, Sebastian G, Vakilzadeh F, Luger T, Strannegard Ö
Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients. Cancer Immunol.
Immunother. (2004) Jan 16 (Epub ahead of print).

Reinhold U
Standards in der Melanomtherapie.
Onkologe (2004) (Suppl. 1)10:S52-S54.

Pföhler C, Cree IA, Ugurel S, Kuwert C, Haass N, Neuber K, Hengge U, Plowman N, Corrie PG, Zutt M, Tilgen W, Reinhold U, Tilgen W.
Treosulfan and gemcitabine in metastatic uveal melanoma patients: first multicenter experience.
Anti-Cancer Drugs (2003) 14:337-340.

Rößler MJ, Rappl G, Muche M, Hasselmann DO, Sterry W, Tilgen W, Reinhold U
No evidence of skin infection with Chlamydia pneumoniae in patients with cutaneous T cell lymphoma.
Clin Microbiol Infect (2003) 9:721-3.

Pföhler C, Haus A, Palmowski A, Ugurel S, Ruprecht KW, Thirkill CE, Tilgen W, Reinhold U
Melanoma-associated retinopathy: high frequency of subclinical findings in patients with melanoma.
Br. J. Dermatol. (2003) 149:74-78.

Neuber K, Reinhold U, Deutschmann A, Pföhler C, Mohr P, Pichlmeier U, Baumgart J, Hauschild A
Second-line chemotherapy of metastatic melanoma with intravenous treosulfan: a phase II multicentre trial.
Melanoma Res. (2003) 13:81-85.

Ugurel S, Tilgen W, Reinhold U
Chemosensitivity testing in malignant melanoma.
Recent Results in Cancer Research (2003) 161:81-92.

Weichenthal M, Neuber K, Mohr P, Trefzer U, Fluck M, Ulrich J, Becker JC, Reinhold U, Volkenandt M, Hauschild A
Second-line treatment of disseminated malignant melanoma with Fotemustine.
Eur. J. Cancer (2003) Suppl. 1 (5):S251.

Stadler R, Kaudewitz P, Plewig G, Proebstle T, Reinhold U, Schöpf E, Sebastian G, Vakilzadeh F, Luger T, Strannegard Ö
Adjuvant treatment of high risk malignant melanoma with dacarbacine and low dose highly purified natural interferon alpha: a controlled, randomized, multicenter trial.
in press

Rappl G, Muche JM, Abken H, Sterry W, Tilgen W, Andre S, Ugurel S, Gabius HJ, Reinhold U, Tilgen W.
CD4+CD7- T cells from the peripheral blood of patients with Sezary syndrome are protected form Galectin-1-mediated cell death.
Leukemia (2002) 16:840-5.

Reinhold U, Schröder CH
Diagnostische Bedeutung frei zirkulierender Nukleinsäuren.
Dtsch Arztebl. (2002);99:A1224-1228.

Haus AH, Palmowski AM, Pföhler C, Reinhold U, Gantenbein C, Thirkill CE, Allgayer R, Tilgen W, Ruprecht KW
Screening for melanoma-associated retinopathy in patients with cutaneous malignant melanoma.
Invest Ophthalmol Vis Sci (2002) im Druck.

Rebmann V, Ugurel S, Tilgen W, Reinhold U, Grosse-Wilde H
Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients.
Int. J. Cancer (2002) 100:580-5.

Palmowski AM, Haus AH, Pföhler C, Reinhold U, Grosse-Wilde H
Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients.
Int. J. Cancer (2002) 100:580-5

Thirkill CE, Allgayer R, Tilgen W, Ruprecht KW, Reinhold U, Grosse-Wilde H
Bilateral multifocal chorioretinopathy changes in a female patient with cutaneous malignant melanoma.
submitted

Reichrath J, Reinhold U, Tilgen W.
Treatment of genito-anal lesions in inflammatory skin diseases with PUVA-cream photochemotherapy: an open pilot study in 12 patients.
Dermatology (2002) 205:245-8.

Ugurel S, Tilgen W, Reinhold U, Tilgen W.
HLA-G in melanoma: a new strategy to escape from immunosurveillance ?
Onkologie (2002);25:129.134.

Ugurel S, Reinhold U, Tilgen W.
Lösliche Serumfaktoren als prognostische Marker des Melanoms: sHLA, sFas und IL-8.
Akt. Dermatol (2002) 28:302-309.

Rappl G, Ugurel S, Tilgen W, Reinhold U, Tilgen W.
Molekularbiologischer Nachweis von Tumormarkern im peripheren Blut und Plasma/Serum von Patienten mit malignem Melanom.
Akt. Dermatol. (2002) 28:310-313.

Ugurel S, Wagner A, Pföhler C, Tilgen W, Reinhold U
Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread.
Br. J. Dermatol (2002) 147:621-3.

Rebmann V, Ugurel S, Tilgen W, Reinhold U, Grosse-Wilde H
Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients.
Int. J. Cancer (2002) 100:580-5.

Reinhardt HJ, Kensey J, Frohmann JP, Willkomm P, Reinhold U, Grunwald F, Biersack HJ, Bender H
Value of tumor marker S-100B in melanoma patients: a comparison to 18F-FDG-PET and clinical data.
Nuklearmedizin (2002) 41:143-7.

Haus AH, Palmowski AM, Pföhler C, Reinhold U, Gantenbein C, Thirkill CE, Allgayer R, Tilgen W, Ruprecht KW.
Melanoma-associated retinopathy: screening for melanoma-associated retinopathy in patients with cutaneous malignant melanoma.
Neuro-Ophthalmology (2002) 27:121-137.

Meineke V, Reichrath J, Reinhold U, Tilgen W.
Verrucae vulgares in childre: successful simulated x-ray treatment (a suggestion-based therapy).
Dermatology (2002) 204:287-9.

Pföhler C, Reinhold U, Tilgen W.
Difficult differential diagnosis: Nonspecific peri-oral papules.
MMW Fortsch. Med. (2002) 144:41-42.

Reinhold U
Cutaneous malignant melanoma: from early diagnosis to gene therapy.
Bull Mem Acad R Med Belg. 2001;156(3-4):212-6

Koch P, Reinhold U, Tilgen W.
Syndrome d´Olmsted
Ann. Dermatol Venerol., (2001) 128:538-40.

Ugurel S, Rappl G, Tilgen W, Reinhold U, Tilgen W.
Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival.
J Clin Oncol (2001) 19:577-583.

Reinhold U, Hauschild A.
Diagnostische Wertigkeit von Tumormarkeruntersuchungen und Verfahren zur prätherapeutischen Chemosensitivitätstestung.
Onkologe (2001) 7:53-60.

Hasselmann DO, Rappl G, Rößler M, Ugurel S, Tilgen W, Reinhold U, Hauschild A.
Detection of tumor-associated circulating mRNA in serum, plasma and blood cell samples from patients with disseminated malignant melanoma.
Oncol. Rep. (2001);8:115-118.

Hauschild A, Eiling S., Reinhold U, Hauschild A.
Adjuvante systemische Therapie des Melanoms.
Onkologe (2001): 7:44-52.

Rappl G, Heuser C, Kapsokefalou A, Ugurel S, Tilgen W, Reinhold U, Abken H.
Normal human skin fibroblasts expose membrane-bound interleukin-15 (IL-15) on the cell surface after long-term stimulation with TNF-alpha.
J. Invest. Dermatol. (2001) 116:102-109.

Seiter S, Stassar M, Rappl G, Reinhold U, Tilgen W, Zöller M.
Upregulation of C4.4A expression during progression of malignant melanoma.
J. Invest. Dermatol. (2001) 116:344-347.

Max N, Willhauck, Wolf K, Thilo F, Reinhold U, Pawlita M, Thiel E, Keilholz U
Reliability of PCR based detection of occult tumor cells: lessons from real-time PCR.
Melanoma Res.(2001) 11:1-8.

Ugurel S, Rappl G, Tilgen W, Reinhold U, Pawlita M, Thiel E, Keilholz U
Increased serum concentration of soluble CD95 (sFas/CD95) correlates with poor prognosis in melanoma patients.
Clin. Cancer Res. (2001), 7:1282-1286.

Reinhold U, Berkin C, Bosserhoff AK, Deutschmann A, Garbe C, Gläser R, Hein G, Krähn G, Peter RU, Rappl G, Schittek B, Seiter S, Ugurel S, Volkenandt M, Tilgen W.
Interlaboratory evaluation of a new reverse transcriptase-polymerase chain reaction (RT-PCR)-based enzyme-linked immunosorbent assay (ELISA) for the detection of circulating melanoma cells: a multicentre study of the Dermatologic Cooperative Oncology Group.
(DeCOG), J. Clin. Oncol. (2001) 19:1723-7.

Kensy J, Bender H, Frohmann JP, Willkomm P, Reinhold U, Grünwald F, Biersack HJ
Value of the tumor marker S-100 in melanoma patients : a comparison to FDG-PET and clinical outcome.
J. Nucl. Med., submitted.

Groß T, Wagner A, Ugurel S, Tilgen W, Reinhold U, Grünwald F, Biersack HJ
Identification of TIA-1+ and granzyme B+ cytotoxic T cells in lichen sclerosus et atrophicus.
Dermatology (2001);202:198-202.

Ugurel S, Rebman V, Tilgen W, Grosse-Wilde H, Reinhold U, Grünwald F, Biersack HJ
Increased sHLA-G serum level in patients with malignant melanoma.
Cancer (2001) 92:369-76.

Seiter S, Ugurel, S, Tilgen W, Reinhold U, Grünwald F, Biersack HJ
Steroid pulse therapy with methylprednisolone in severe alopecia areata: A prospective study of 30 patients.
Dermatology (2001);202:230-234.

Rappl G, Abken H, Seiter S, Tilgen W, Ugurel S, Reinhold U, Grünwald F, Biersack HJ
Membrane IL-15 on TNF a-stimulated fibroblasts rescues the CD7-negative subset of CD4+ memory T cells from accelerated apoptosis: a mechanism for their lesional accumulation and in chronic inflammatory skin diseases.
Cell Death Diff (2001); 8:395-402.

Gantenbein C, Seiter S, Weik R, Reinhold U, Ruprecht KW, Tilgen W.
Manifestation oculaire de Télangiectasies essentielles progressives.
J. Fr. ophtalmol. (2001) 24,1:45-48

Reinhold U, Ruprecht KW, Tilgen W.
Postoperative progressive Gangrän.
hautnah dermatologie (2001) 17:14-15.

Reinhold U, Ruprecht KW, Tilgen W.
Herpes genitalis in der Schwangerschaft.
hautnah dermatologie (2001) 2:62-63.

Koch P, Reinhold U, Tilgen W.
Olmsted syndrome.
Ann. Dermatol. Venereol (2001) 128:538-540.

Hasselmann DO, Rappl G, Tilgen W, Reinhold U, Tilgen W.
Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum.
Clin. Chem. (2001) 47:1488-9.

Rappl G, Hasselmann DO, Rößler M, Ugurel S, tilgen W, Reinhold U, Tilgen W.
Detection of tumor-associated circulating mRNA in patients with disseminated malignant melanoma.
Ann. N. Y. Acad. Sci. (2001) 945:189-91.

Reinhold U
Acne fulminans.
hautnah dermatologie (2000), 6:254-255.

Palmowski A, Haus A, Pföhler C, Reinhold U, Gantenbein C, Allgayer R, Scherer V, Tilgen W, Ruprecht KW
Okuläre Befunde bei 28 Patienten mit malignem Melanom.
Der Augenspiegel (2000);12:33-34.

Reinhold U, Grünwald F, Biersack HJ
Systemische Therapie beim Akne-Notfall.
MMW-Fortschr. Med. (2000) 5: 41-42

Pföhler C, Ugurel S, Wagner A, Tilgen W, Reinhold U, Koch P, Tilgen, W.
Interferon-alpha-associated development of bullous lesions in mycosis fungoides.
Dermatology (2000) 200:51-53.

Reinhold U, Buttgereit F.
Hochdosis-Steroid-Pulstherapie – Gibt es Indikationen in der Dermatologie ?
Hautarzt (2000) 51:738-745.

Seiter S, Ugurel S, Tilgen W, Reinhold U
Use of high dose methylprednisolone pulse therapy in patients with progressive stable vitiligo
Int. J. Dermatol (2000) 39: 624-27.

Ugurel S, Pföhler C, Tilgen W, Reinhold U
S100-beta serum protein – a new marker in the diagnosis and monitoring of Langerhans cell histiocytosis.
Br. J. Dermatol.(2000) 143:201-202.

Abken H, Hombach A, Heuser C, Reinhold U
A novel strategy in the elimination of disseminated melanoma cells: chimeric receptors endow T cells with tumor specificity.
Recent Res. Cancer Res. (2000) 158:249-264.

Seiter S, Rappl G, Tilgen W, Ugurel S, Reinhold U
Facts and pitfalls in the detection of tyrosinase-mRNA in the blood of melanoma patients by RT-PCR. Recent Res.
Cancer Res. (2000) 158: 105-112.

Liu L, Abken H, Pföhler C, Rappl G, Tilgen W, Reinhold U
Accumulation of CD4+CD7- T cells in inflammatory skin lesions: Evidence for preferential adhesion to vascular endothelial cells.
Clin. Exp. Immunol. (2000) 121:94-99.

Rappl G, Muche JM, Abken H, Sterry W, Tilgen W, Ugurel S, Reinhold U
CD4+CD7- T cells compse the dominant T cell clone in the peripheral blood of patients with Sezary syndrome.
J. Am. Acad. Dermatol. (2001) 44:456-461.

Reinhold U, Ugurel S, Tilgen W, Kadiata MM, Olivares, Bakkali Nadi A, Malaisse WJ.
Antitumoral action of 2-deoxy-D-glucose tetraacetate in human melanoma cells.
Oncol. Rep. (2000) 7:1093-1097.

Pföhler Ch., Reinhold U, Ugurel S, Tilgen W, Kadiata MM, Olivares, Bakkali Nadi A, Malaisse WJ.
Kutane Leishmaniose.
hautnah dermatologie (2000) 16:160-161.

Reinhold U, Tilgen W (Eds.)
Minimal Residual Disease in Melanoma. Recent Results in Cancer Research 158
Springer Verlag Berlin, Heidelberg, New York, 2000.

Reinhold U, Tilgen W (Eds.)
Praxisorientierte Kombinationstherapie bei atopischer Dermatitis.
hautnah dermatologie (2000) 16:167-169.

Reinhold U, Tilgen W (Eds.)
Juckreiz lindern – Entzündung bekämpfen.
MMW Fortschr. Med. (2000) 142:38-40

Reinhold U, Tilgen W (Eds.)
Cortisone pulse therapy in dermatology: controlled use promises high rate of success.
MMW Fortschr. Med. (1999) 141:78-9.

Seiter, S., Ugurel, S., Tilgen, W., Reinhold U
Generalisierter Histamin-Flush mit lokalisierter Blasenbildung nach Provokation des Darier`schen Zeichens.
Akt. Dermatol. (1999) 25:70-72.

Reinhold U, Tilgen W.
8. Jahrestagung der Arbeitsgemeinschaft Dermatologische Onkologie (ADO).
Forum DKG 14:21-23, 1999.

Reinhold U, Liu, L., Lüdtke-Handjery, H.Ch., Heuser, C., Hombach, A., Wang, X., Gorbachev, A., Tilgen, W., Ferrone, S., Abken, H.
Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor.
J. Invest. Dermatol. (1999) 112:744-750.

Naderi, S., Hofmann, P., Seiter, S., Tilgen, W., Abken, H., Reinhold U, Liu, L., Lüdtke-Handjery, H.Ch., Heuser, C., Hombach, A., Wang, X., Gorbachev, A., Tilgen, W., Ferrone, S., Abken, H.
CD2 mediated CD59 stimulation in normal epidermal keratinocytes results in secretion of IL-1 a, UL-6, and GM-CSF: implications for the interaction of keratinocytes with intraepidermal T lymphocytes.
Int. J. Mol. Med. (1999) 3:609-614.

Ugurel, S., Seiter, S., Rappl, G., Stark, A., Tilgen, W., Reinhold U
Heterogeneous susceptibility to FasR/CD95-induced apoptosis in melanoma cells correlates with the level of bcl-2 and bcl-x expression and is sensitive to modulation by interferong
Int. J. Cancer (1999) 82:727-736

Hombach A, Pohl C, Reinhold U, Abken H. Grafting T.
Cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant disease.
Hybridoma (1999) 18:57-61.

Seiter S., Ugurel S, Tilgen W, Reinhold U, Abken H. Grafting T.
An oculo-cutaneous manifestation of essential progressive teleangiectasia.
Br. J. Dermatol. (1999) 140:969-971.

Seiter S., Ugurel S, Tilgen W, Reinhold U, Abken H. Grafting T.
Multiple granular cell tumors and growth hormone deficiency in a child.
Ped. Dermatol (1999) 16:308-310.

Reinhold U, Seiter S, Ugurel S, Tilgen W.
Treatment of progressive pigmented purpura with oral bioflavonoids and ascorbic acid: An open pilot study in three patients
J. Am. Acad. Dermatol. (1999), 41:207-208.

Cree IA, Neale MH, Myatt NE, de Takats PG, Hall P, Grant J, Kurbacher CM, Reinhold U, Neuber K, MacKie RM, Chana J, Weaver P, Khoury GG, Sartori DC, Andreotti PE
Heterogeneity of chemosensitivity of metastatic cutaneous melanoma.
Anti-Cancer Drugs (1999) 10:437-444.

Reinhold U, Tilgen W.
8. Jahrestagung der Arbeitsgemeinschaft Dermatologische Onkologie ADO
Akt. Dermatol. (1999) 25:195-198.

Seiter S, Ugurel S, Tilgen W, Reinhold U
Successful treatment of progressive vitiligo with high-dose intravenous methylprednisolone „pulse“ therapy.
Dermatology (1999) 199:261-262.

Reinhold U, Dill-Müller D, Koch P
Notfälle in der Dermatologie. Ein aktueller Leitfaden für Klinik und Praxis.
Georg Thieme Verlag, Stuttgart, New York (1999).

Dill-Müller D, Reinhold U, Koch P, Tilgen, W.
128. Jahrestagung der Vereinigung Südwestdeutscher Dermatologen_ Region Südwest der Deutschen Dermatologischen Akademie (DDA) 8./9. Oktober 1999, Homburg/Saar.
Z. Hautkr. (1999) 74: 524-537.

Reinhold U, Malaisse, W.J.
Cytotoxic action of 2-deoxy-D-glucose tetraacetate upon human lymphocytes, fibroblasts and melanoma cells.
Int. J. Mol. Med. (1998) 1:427-430.

Abken, H., Hombach, A., Reinhold U, Ferrone, S.
Can combined T cell- and antibody-based immunotherpay outsmart tumor cells ?
Immunol. Today (1998) 19:2-5.

Reinhold U, Seiter, S., Wagner, A., Tilgen, W.
Pigmentatio maculosa eruptiva idiopathica.
Akt. Dermatol. (1998) 24:77-79.

Reinhold U, Dill-Müller D, Rass K, Seiter S, Ugurel S, Tilgen W.
8. Jahrestagung der Arbeitsgemeinschaft Dermatologische Onkologie (ADO) 2./3. Oktober 1998, Homburg/Saar.
Z. Hautkr. (1998) 73:624-649.

Reinhold U, Seiter S, Rass K, Reichrath J, Tilgen W.
Neue Entwicklungen in der Pathogenese, Diagnostik und Therapie maligner Tumorn.
Magazin Forschung, Universität des Saarlandes (1998) 1:16-27.

Wagner, S.N., Wagner, C., Reinhold U, Funk, R., Zöller, M., Goos, M.
Predominant expression of CD44 splice variant v10 in malignant and reactive human skin lymphocytes.
J. Invest. Dermatol. (1998) 111:464-471.

Reinhold U, Lüdtke-Handjery, H.Ch., Schnautz, S., Kreysel, H.W., Abken, H.
The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression.
J. Invest. Dermatol. (1997) 108:166-169.

Reinhold U, Hartl., Ch., Hering, R., Hoeft, A., Kreysel, H.W.
Fatal rhabdomyolysis and multiple organ failure associated with adjuvant high dose interferon-alpha in malignant melanoma.
Lancet (1997) 540-541.

Bender, H., Grapow, M., Schomburg, A., Reinhold U, Biersack, H.J.
Effects of diagnostic application of monoclonal antibody on survival in melanoma patients.
Hybridoma (1997)16:65-68.

Reinhold U, Hartl, Ch., Gerdsen, R., Kreysel, H.W.
Treatment of aquagenic pruritus using recombinant interferon-alpha.
Br. J. Dermatol. (1997) 137:324-325.

Abken, H., Hombach, A., Heuser, C., Sircar, R., Reinhold U
Chimeric T cell receptors: highly specific tools to target cytotoxic T lymphocytes to tumor cells.
Cancer Treat. Rev. (1997) 23:97-112.

Reinhold U, Abken, H.
CD4+CD7- T cells. a separate subpopulation of memory T cells ?
J. Clin. Immunol. (1997) 17:265-271.

Reinhold U, Frick, M., Fischer, J., Schupp, G., Kreysel, H.W.
High-dose chemotherapy with autologous stem cell transplantation in a patient with advanced-stage CD30+ anaplastic large cell lymphoma of the skin.
Br. J. Dermatol. (1996) 134:811-813.

Reinhold U, Bruske, Th., Kreysel, H.W.
Dacarbazine, vincristine, bleomycin and lomustine plus natural interferon-alpha for metastatic melanoma.
Eur. J. Cancer (1996) 32A:180.

Reinhold U, Bruske, Th., Pauleit, D., Schupp, G., Uerlich, M.
Das metastasierte Merkelzell-Karzinom der Haut- Therapeutische Aspekte anhand eines Fallberichtes.
Akt. Dermatol. (1996) 22:173-176.

Reinhold U
Neue Diagnostik- und Therapiekonzepte in der dermatologischen Onkologie.
Dt. Derm. (1996) 44:265-266.

Liu, L.D., Foer, A., Sesterhenn, J., Reinhold U
CD2-mediated stimulation of the naive CD4+ T cell subset promotes the devels.
Immunology (1996) 88:207-213.

Reinhold U, Bruske, Th., Schupp, G.
Paraneoplastic urticaria in a patient with ovarian carcinoma.
J. Am. Acad. Dermatol. (1996) 35:988-989.

Reinhold U, Liu, L., Sesterhenn, J., Abken, H.
CD7-negative T cells represent a separate differentiation pathway in a subset of postthymic helper T cells.
Immunology (1996) 89:391-396.

Reinhold U, Abken, H.
Cutaneous T-cell lymphoma: molecular genetics, immunology and pathogenesis.
Eur. J. Cancer (1995) 31A:793-799.

Reinhold U, Abken, H.
Cutaneous T-cell lymphoma: molecular genetics, immunology and pathogenesis.
Eur. J. Cancer (1995) 31A:793-799.

Reinhold U, Herpertz, M., Kukel, S., Uerlich, M., Kreysel, H.W.
Induction of nuclear contour irregularity during T-cell activation via the T-cell receptor/CD3 complex and CD2 antigens in the presence of phorbol esters.
Blood (1994) 3: 703-706.

Moll, M., Reinhold U, Kukel, S., Abken, H., Müller, R., Oltermann, I., Kreysel, H.W.
CD7-negative helper T cells accumulate in inflammatory skin lesions.
J. Invest. Dermatol. (1994) 102:328-332.

Schomburg, A., Stoschus B., Reinhold U, Hartl., C., Malfertheiner P., Biersack, H.J.
Die Differentialdiagnose von Motilitätsstörungen mittels Ösophagus-Transit-Szintigraphie.
Endoskopie heute (1994) 2:157-162.

Reinhold U
Therapiekonzepte bei Sarkomen der Haut.
Hautnah Derm. (1994) 10: 244-253.

Reinhold U
Notfälle und supportive Therapiemaßnahmen in der dermatologischen Onkologie.
Z. Hautkr. (1994) 69: 505-510.

Menzel, Ch., Reinhold U, Grünwald, von Smekal, A., Uerlich, M., Rieker, O., Hotze, A.L., Biersack, H.J.
Cerebral blood flow in Sneddon syndrome.
J. Nucl. Med. (1994) 35: 461-464.

Kukel, S., Reinhold U, Oltermann, I., Kreysel, H.W.
Progressive increase of CD7- T cells in human blood lymphocytes with ageing.
Clin. Exp. Immunol. (1994) 98: 163-168.

Reinhold U, Abken, H., Kukel, S., Moll, M., Müller, R., Oltermann, I., Kreysel, H.W.
CD7- T cells represent a subset of normal human blood lymphocytes.
J. Immunol. (1993) 150: 2081-2089.

Reinhold U, Kukel, S., Brzoska, J., Kreysel, H.W.
Systemic interferon-gamma treatment in severe atopic dermatitis.
J. Am. Acad. Dermatol. (1993) 29: 58-63.

Malaisse, W.J., Malaisse-Lagae, F., Kukel, S., Reinhold U, Sener, A.
Could non-insulin-dependent diabetes mellitus be attributable to a deficiency of FAD-linked glycerophosphate dehydrogenase ?
Biochem. Med. Metab. Biol. (1993) 50: 226-232.

Schomburg, A.G., Briele, B., Bender, H., Reinhold U, Menzel, C., Rieker, O., Hotze, A.L., Biersack, H.J.
Radioimmunodetection of melanoma.
Diagn. Oncol. (1993) 3:101-106.

Reinhold U, Kukel, S., Goeden, B., Neumann, U., Kreysel, H.W.
Therapie der atopischen Dermatitis – Tips aus der Klinik.
Der Deutsche Dermatologe (1992) 2: 1-2.

Wehrmann, W., Reinhold U, Goeden, B., Kukel, S., Neumann, U., Wehrmann, W., Kreysel, H.W.
In vitro expanded skin-infiltrating lymphocytes from atopic dermatitis lesions secrete high levels of interleukin-4 and low levels of interferon-gamma.
Skin Pharmacol. (1991) 4: 158-164.

Reinhold U, Abken, H., Kukel, S., Goeden, B., Uerlich, M., Neumann, U., Kreysel, H.W.
Tumor infiltrating lymphocytes isolated from a Ki-1+ large cell lymphoma of the skin: phenotypic characterization and analysis of cytokine secretion.
Cancer (1991) 68: 2155-2160.

Reinhold U, Kukel, S., Goeden, B., Neumann, U., Kreysel, H.W.
Functional analysis of skin-infiltrating lymphocytes in atopic dermatitis.
Clin. Exp. Immunol. (1991) 86: 444-448.

Reinhold U, Kukel, S., Goeden, B., Neumann, U., Wehrmann, W., Kreysel, H.W.
Interleukin-4 promotes the expansion of skin-infiltrating lymphocytes from atopic dermatitis in vitro.
J. Invest. Dermatol. (1991) 96: 370-375.

Reinhold U
Interferon-gamma: a potential role in the treatment of severe atopic dermatitis.
Int. J. Dermatol. (1991) 30: 477-478.

Reinhold U, Petrow, W.
Hautsymptome bei nicht HIV-bedingter Immundefizienz.
Z. Hautkr. (1991) 66: 491-494.

Reinhold U
Systemische Chemotherapie maligner Erkrankungen der Haut.
Onkologie (1991) 14: 137-146.

Wehrmann, W., Reinhold U, Kukel, S., Franke, N., Uerlich, M., Kreysel, H.W.
Selective alterations in natural killer cell subsets in patients with atopic dermatitis.
Int. Arch. Allergy Appl. Immunol. (1990) 92: 318-322.

Reinhold U, Pawelec, G., Fratila, A., Leippold, S., Bauer, R., Kreysel, H.W.
Phenotypic and functional characterization of tumor infiltrating lymphocytes in mycosis fungoides: continuous growth of CD4+ CD45R+ T-cell clones with suppressor-inducer activity.
J. Invest. Dermatol. (1990) 94: 304-309.

Reinhold U, Wehrmann, W., Kukel, S., Kreysel, H.W.
Evidence that defective interferon-gamma production in atopic dermatitis patients is due to intrinsic abnormalities.
Clin. Exp. Immunol. (1990) 79: 374-379.

Reinhold U, Wehrmann, W., Kukel, S., Kreysel, H.W.
Recombinant interferon- gamma in severe atopic dermatitis.
Lancet (1990) i:1282.

Reinhold U, Biltz, H., Bayer, W., Schmidt, K.H.
Serum sents with malignant melanoma.
Acta Derm. Venerol. (1989) 2: 132-136.

Wehrmann, W., Reinhold U, Pawelec, G., Wernet, P., Kreysel, H.W.
In vitro generation of IFN-gamma in relationship to in vivo concentration of IgE and IgG subclasses and FcRL/CD23 positive circulating lymphocytes in patients with severe atopic dermatitis (AD).
Acta Derm. Venereol. (1989) 144: 127-130.

Reinhold U, Pawelec, G., Enczmann, J., Wernet, P.
Class-specific effects of selenium on PWM-driven human antibody synthesis in vitro.
Biol. Trace Element Res. (1989) 20: 45-58.

Reinhold U, Pawelec, G., Wehrmann, W., Kukel, S., Oehr, P., Kreysel, H.W. Cytokine
Cytokine release from cultured peripheral blood mononuclear cells of patients with severe atopic dermatitis.
Acta Derm. Venerol. (1989) 69: 497-502.

Reinhold U, Bauer, R.
Eine klinisch-immunologische Analyse über den Stellenwert natürlicher Killerzellen bei dermatologischen Krankheiten.
Hautarzt (1988) 39: 129-135.

Reinhold U
Malnutrition und Immunsystem.
VitaMinSpur (1988) 3: 7-13.

Pawelec, G., Busch, F., Reinhold U Rehbein, A., Balko, I., Bühring, H.J.
Division of human helper T cells into two sets on the basis of the induction of anti-tumor cytotoxicity by phorbol ester and calcium ionophore.
Eur. J. Immunol. (1988) 18: 1147-1150.

Reinhold U, Pawelec, G., Wehrmann, W., Herold, M., Wernet, P., Kreysel, H.W.
Immunoglobulin E and immunoglobulin G generation of interferon-gamma and neopterin in patients with severe atopic dermatitis.
Int. Arch. Allergy Appl. Immunol. (1988) 87: 120-126.

Reinhold U, Bauer, R.
Malnutrition und Immunsystem.
Z. Hautkr. (1987) 62: 60-73.

Reinhold U, Bauer, R.
Specific application of single nutrients as a basic treatment in immunostimulating therapy.
Medical Hypoth. (1987) 22: 159-169.

Reinhold, U, Wehrmann, W., Bauer, R., Kreysel, H.W.
Defizit natürlicher Killerzellen (NK-Zellen) im peripheren Blut bei atopischer Dermatitis.
Hautarzt (1986) 37: 438-443.

Reinhold U, Bauer, R., Kreysel, H.W.
Klinisch relevante Aspekte der zellulären Immunreaktivität.
Akt. Dermatol. (1986) 12: 149-152.

Reinhold U, Rosen-Uzelac, G.
Parainfektiöse Neuritis nervi optici bei Herpes zoster ophthalmicus.
Akt. Dermatol. (1986) 12: 149-152.

  • 1. Vorsitzender Onkoderm e.V.
  • Deutsche Dermatologische Gesellschaft (DDG)
  • Arbeitsgemeinschaft Dermatologische Onkologie ADO der Deutschen Krebsgesellschaft (DKG)
  • Berufsverband der Deutschen Dermatologen (BVDD)
  • Arbeitsgemeinschaft Dermatologische Forschung (ADF)
  • European Society for Dermatological Research (ESDR)
  • Society for Investigative Dermatology (SID)
  • EORTC Cutaneous Lymphoma Group
  • International Society for Cutaneous Lymphomas (ISCL)
  • International Society of Dermatology: Tropical, Geographic and Ecologic
  • European Academy of Dermatology and Venereology (EADV)

Videos

Warum bin ich Mediziner geworden?

Prof. Dr. med. Reinhold erklärt in einem kurzen Video, wie er zur Medizin gekommen ist und was ihn daran begeistert.

Die Besonderheiten unserer Diagnostik

Prof. Dr. med. Reinhold erklärt, wofür das MVZ Dermatologische Zentrum Bonn steht.

Vereinbaren Sie jetzt einen Termin!

Wir beraten und kümmern uns gerne kompetent um Ihre Anliegen. Jetzt Termin telefonisch, per E-Mail oder online vereinbaren.

T 0228 / 227 209 200 info@derma-bonn.de

Termin
buchen